Next-generation antibody drug market seen topping $32.8 billion by 2030

The Business Research Company says the next generation antibody drug market is headed for rapid growth through 2030, driven by cancer demand, engineering advances and pharma investment. North America and the U.S. are expected to lead, while antibody-drug conjugates emerge as the largest product segment.

Why it matters: - The next generation antibody drug market is moving from niche to mainstream inside pharmaceuticals. - The category is projected to exceed $33 billion by 2030, according to The Business Research Company. - The market could capture about 65% of the broader drug development services market by 2030. - Antibody-drug conjugates are shaping the strongest growth in targeted cancer treatment.

What happened: - The Business Research Company released its Next Generation Antibody Drug Global Market Report 2026 on Oct. 26, 2026. - The report projects the market at $32.82 billion by 2030. - The market is forecast to grow at a 15% compound annual growth rate through 2030. - North America is projected to be the largest regional market, at $15 billion by 2030. - The U.S. is expected to be the largest country market, at $14 billion by 2030.

The details: - North America is forecast to grow from $8 billion in 2025 to $15 billion in 2030, a 14% CAGR. - The U.S. market is projected to rise from $7 billion in 2025 to $14 billion in 2030, a 15% CAGR. - Antibody-drug conjugates are expected to be the largest product type in 2030, with 46% of the market, or $15 billion. - The report breaks the market into checkpoint inhibitors, immune modulators, receptor blockers, targeted cytotoxic agents and neutralizing antibodies. - Delivery routes include intravenous, subcutaneous and intramuscular administration. - Key applications include oncology, autoimmune diseases, infectious diseases and other uses. - End users include hospitals, research institutions, specialty clinics and other healthcare providers. - The report says monoclonal antibodies could grow by $3 billion from 2025 to 2030. - Bispecific antibodies are projected to add $4 billion over the same period. - Antibody-drug conjugates are projected to add $8 billion. - Other antibody types are projected to add $1 billion. - Daiichi Sankyo Company, Limited was named the top global player in 2025 with a 5% market share. - The report also lists AbbVie, AstraZeneca, Roche/Genentech, Pfizer/Seagen, Boehringer Ingelheim, Gilead Sciences, Genmab, Takeda, Kyowa Hakko Kirin, ADC Therapeutics, Akeso, Astellas, Xencor, GSK, Mablink Bioscience, Synaffix, Araris Biotech, Rakuten Medical, Zai Lab and Mersana Therapeutics among major competitors. - The top 10 companies held 29% of total revenues in 2025, signaling a moderately fragmented market. - Raw material suppliers named in the report include Roche, Amgen, Pfizer, Novartis, Merck, Sanofi, Bristol Myers Squibb, AstraZeneca, GSK, Eli Lilly, AbbVie, Takeda, Biogen, Regeneron, Genmab, Seagen, Daiichi Sankyo, Chugai, ImmunoGen, Xencor, MacroGenics, Sutro Biopharma, Zymeworks, Iovance Biotherapeutics and ADC Therapeutics. - Wholesalers and distributors named in the report include McKesson, Cardinal Health, Cencora, AmerisourceBergen Distribution Services, Medipal Holdings, Owens and Minor, Sinopharm, Shanghai Pharmaceuticals, Phoenix Pharmahandel, Zuellig Pharma, Walgreens Boots Alliance Distribution, Alliance Healthcare, Movianto, H. D. Smith, Morris and Dickson, Anda, Uniphar, Theramex Distribution Services, Nipro, Biocodex, Alloga Logistics Services and Parata Systems Distribution Solutions. - End users listed in the report include Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, UCSF Health, Oxford University Hospitals NHS Foundation Trust, University College London Hospitals NHS Foundation Trust, Charité Universitätsmedizin Berlin, NIH Clinical Center, St. Jude Children's Research Hospital, Labcorp Drug Development, Quest Diagnostics, Apollo Hospitals, Fortis Healthcare, Narayana Health, Medanta, AIIMS New Delhi, Singapore General Hospital, National University Hospital Singapore, Tokyo University Hospital, Samsung Medical Center and Sheba Medical Center. - The report says the market is supported by expanding oncology and autoimmune disease demand, stronger regulatory support for accelerated biologics approvals, collaborations between biotech and big pharma, and improved biomanufacturing capabilities.

Between the lines: - The report frames cancer, especially hard-to-treat solid tumors, as the main demand engine for next-generation antibody drugs. - Antibody engineering advances, including ADCs, bispecific antibodies and Fc-engineering, are widening the field beyond traditional monoclonal antibodies. - Venture capital and large pharma are helping push discovery, clinical development and commercialization faster. - The competitive landscape remains open enough for specialist biopharma firms, but development costs and regulatory hurdles still favor companies with strong pipelines and manufacturing scale. - The report highlights a broader shift toward precision medicine, where targeted payload delivery and lower systemic toxicity are central selling points.

What's next: - BioNTech SE and Duality Biologics are advancing BNT325/DB-1305, which received FDA Fast Track designation in January 2024 for platinum-resistant ovarian cancer. - The report expects partnerships, licensing deals and strategic funding to keep accelerating launches and pipeline growth. - Companies are likely to keep expanding biomanufacturing capacity and engineering platforms to compete in oncology and immunology. - Market share gains will likely hinge on clinical success, regulatory progress and commercialization speed.

The bottom line: - Next-generation antibody drugs are becoming a major growth area in pharma, led by cancer-focused ADCs and a fast-expanding pipeline of targeted therapies.